Nora A. Janjan, MD

Articles

Preoperative Chemoradiation for Locally Advanced Rectal Cancer: Emerging Treatment Strategies

Christopher H. Crane, MD;Nora A. Janjan, MD;Kathy Mason, MS;Luka Milas, MD, PhD

May 2nd 2002

Over the past decade, patients with locally advanced rectal cancer at The University of Texas M. D. Anderson Cancer Center have been managed with preoperative chemoradiation. Patients achieving a complete clinical response to preoperative chemoradiation have had better pelvic tumor control, sphincter preservation, and overall survival than those with gross residual disease. Some patients achieving a complete clinical response have even had rectal-preserving surgery (full-thickness local excision).

Phase I Study of Irinotecan and Concurrent Radiation Therapy for Upper GI Tumors

Ritsuko Komaki, MD;Nora A. Janjan, MD;Jaffer A. Ajani, MD;Patrick M. Lynch, MD;Jackie S. Fairweather, RN;Isaac Raijman, MD;George R. Blumenshein, MD;Linus Ho, MD, PhD;Peter W. T. Pisters, MD;Barry W. Feig, MD;Garrett L. Walsh, MD;Richard Pazdur, MD

December 3rd 2000

Irinotecan (Camptosar) is an active chemotherapeutic agent for lung, gastric, esophageal, and colorectal cancers and a potent radiosensitizer. This phase I study was designed to assess the maximum tolerated dose of weekly